Expression of IGF-1R/NF-kappa B and multi-drug resistance in insulin resistance-HepG2 and HepG2.2.15 cells in vitro
Wang Yilang,Yin Dian,Yang Li,et al.
Department of Oncology,Research Center of Clinical Medicine,First People’s Hospital Affiliated to Nantong University,Nantong,226001,Jiangsu Province,China
Wang Yilang,Yin Dian,Yang Li,et al.. Expression of IGF-1R/NF-kappa B and multi-drug resistance in insulin resistance-HepG2 and HepG2.2.15 cells in vitro[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 704-708.
[1] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics. 2012.CA Cancer J Clin,2015,65(2):87-108. [2] Yang JD,Roberts LR. Hepatocellular carcinoma:A global view. Nat Rev Gastroenterol Hepatol,2010,7(8):448-458. [3] Shikata K,Ninomiya T,Kiyohara Y. Diabetes mellitus and cancer risk:review of the epidemiological evidence. Cancer Sci,2013,104(1):9-14. [4] Chettouh H,Lequoy M,Fartoux L,et al. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int,2015,35(10):2203-2217. [5] Ohta Y,Tanizawa Y.Insulin secretion and insulin resistance. Nihon Rinsho,2013,71(11):1936-1940. [6] De Minicis S,Agostinelli L,Rychlicki C,et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH.PLoS One,2014,9(5):e97136. [7] Lopes-Rodrigues V,Seca H,Sousa D,et al. The network of P-glycoprotein and microRNAs interactions. Int J Cancer,2014,135(2):253-263. [8] Shi Y,Wang SY,Yao M,et al. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA. World J Gastroenterol,2015,21(45):12814-12821. [9] 姚敏,顾星,姚登福,等. 肝癌患者核因子-κB异常表达及转录干预对多药耐药的逆转效果. 中华医学杂志,2016,96(10):761-766. [10] 吴玮,姚敏,王以浪,等. TNF-α/NF-κB通路干预对肝癌多药耐药相关P-gp表达的影响.南通大学学报(医学版),2013,33(1):13-17. [11] Nawa A,Fujita-Hamabe W,Tokuyama S. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Life Sci,2011,89(23-24):834-838. [12] Kobori T,Harada S,Nakamoto K,et al. Functional alterations of intestinal P-glycoprotein under diabetic conditions.Biol Pharm Bull,2013,36(9):1381-1390. [13] Siddique A,Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis,2011,15(2):281-296. [14] Sugimoto K,Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011,41(10):911-920. [15] Starley BQ,Calcagno CJ,Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma:a weighty connection. Hepatology,2010,51(5):1820-1832. [16] Wang P,Kang D,Cao W,et al. Diabetes mellitus and risk of hepatocellular carcinoma:a systematic review and meta-analysis.Diabetes Metab Res Rev,2012,28(2):109-122. [17] Chao LT,Wu CF,Sung FY,et al. Insulin,glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis,2011,32(6):876-881. [18] Burnol AF,Morzyglod L,Popineau L. Cross-talk between insulin signaling and cell proliferation pathways. Ann Endocrinol (Paris),2013,74(2):74-78. [19] 姚宁华,姚登福,董志珍,等. 足叶苦素抑制胰岛素样生长因子I受体表达对肝癌细胞增殖与运动的影响. 中华肝脏病杂志, 2013,21(5):376-380. [20] Yan XD,Yao M,Wang L,et al. Overexpression of insulin-like growth factor-Ireceptor as a pertinent biomarker for hepatocytes malignant transformation. World J Gastroenterol,2013,19(36):6084-6092. [21] Hu Y,Li C,Li H,et al. Resveratrol-mediated reversal of tumor multi-drug resistance. Curr Drug Metab,2014,15(7):703-710. [22] Nawa A,Fujita Hamabe W,Tokuyama S. Altered intestinal P-glycoprotein expression levels in a monosodium glutamate-induced obese mouse model. Life Sci,2011,89(23-24):834-838. [23] Nawa A,Fujita Hamabe W,Tokuyama S. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci,2010,86(11-12):402-409.